Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk.

PloS One
Pablo TebasDavid Katzenstein

Abstract

Concern about costs and antiretroviral therapy (ART)-associated toxicities led to the consideration of CD4 driven strategies for the management of HIV. That approach was evaluated in the SMART trial that reported an unexpected increase of cardiovascular events after treatment interruption (TI). Our goal was to evaluate fasting metabolic changes associated with interruption of antiretroviral therapy and relate them to changes of immune activation markers and cardiovascular risk. ACTG 5102 enrolled 47 HIV-1-infected subjects on stable ART, with <200 HIV RNA copies/mL and CD4 cell count >or=500 cells/microL. Subjects were randomly assigned to continue ART for 18 weeks with or without 3 cycles of interleukin-2 (IL-2) (cycle = 4.5 million IU sc BID x 5 days every 8 weeks). After 18 weeks ART was discontinued in all subjects until the CD4 cell count dropped below 350 cells/microL. Glucose and lipid parameters were evaluated every 8 weeks initially and at weeks 2, 4, 8 and every 8 weeks after TI. Immune activation was evaluated by flow-cytometry and soluble TNFR2 levels. By week 8 of TI, levels of total cholesterol (TC) (median (Q1, Q3) (-0.73 (-1.19, -0.18) mmol/L, p<0.0001), LDL, HDL cholesterol (-0.36(-0.73,-0.03)mmol/L, p = 0.0007...Continue Reading

Associated Clinical Trials

References

Aug 8, 1991·The New England Journal of Medicine·M J StampferC H Hennekens
Mar 1, 1989·Acta paediatrica Scandinavica·A SartorioG Faglia
Jul 1, 1997·The Journal of Infection·Y GérardP Wattre
Dec 28, 1999·Proceedings of the National Academy of Sciences of the United States of America·R T DaveyH C Lane
Jan 10, 2002·Proceedings of the National Academy of Sciences of the United States of America·Diane V Havlir
Feb 2, 2002·Current Atherosclerosis Reports·John A Farmer, Guillermo Torre-Amione
Mar 6, 2002·Circulation·Peter LibbyAttilio Maseri
Jun 19, 2002·Trends in Cardiovascular Medicine·Burkhard LudewigHans Hengartner
Dec 20, 2002·Nature·Peter Libby
Feb 21, 2003·The New England Journal of Medicine·Samuel A BozzetteThomas A Louis
Jun 12, 2003·JAMA : the Journal of the American Medical Association·Sharon A RiddlerLawrence A Kingsley
Nov 25, 2003·The New England Journal of Medicine·Nina Friis-MøllerUNKNOWN Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group
Jan 7, 2005·The New England Journal of Medicine·Steven Grinspoon, Andrew Carr
Feb 4, 2006·Journal of Clinical Microbiology·Daniel J Skiest
Jun 9, 2006·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Keith HenryUNKNOWN A5102 Study Team of the AIDS Clinical Trials Group
Jun 17, 2006·Nature Reviews. Immunology·Göran K Hansson, Peter Libby
Aug 8, 2006·Journal of Clinical Microbiology·Simon J TsiourisWafaa El-Sadr
Nov 2, 2006·PLoS Biology·Zahedi MujawarDmitri Sviridov
Nov 30, 2006·PLoS Medicine·Andrew Carr, Daniel Ory
Apr 27, 2007·The New England Journal of Medicine·UNKNOWN DAD Study GroupJens D Lundgren

❮ Previous
Next ❯

Citations

Dec 16, 2011·HIV Therapy·Jordan E Lake, Judith S Currier
Jan 5, 2012·Clinical Lipidology·Carlos D Malvestutto, Judith A Aberg
Oct 22, 2014·Nature Reviews. Cardiology·Markella V ZanniPeter Reiss
Dec 3, 2009·Journal of Leukocyte Biology·Suzanne M CroweMichael Bukrinsky
Dec 17, 2009·American Journal of Epidemiology·Stephen R ColeMichael S Saag
Jul 27, 2010·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Fiona C LampeUNKNOWN INSIGHT SMART Study Group
Mar 30, 2011·AIDS Research and Human Retroviruses·Lance T VernonBenigno Rodriguez
Sep 6, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michael J MugaveroUNKNOWN Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) Cohort Study
Nov 3, 2012·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Stefan EsserNico Reinsch
Dec 23, 2009·The Journal of Antimicrobial Chemotherapy·Satyajit Das
Feb 11, 2011·Current Infectious Disease Reports·Diixa Patel, Lawrence R Crane
May 10, 2013·Journal of Cardiovascular Medicine·Davide GibelliniMaria Carla Re
Jun 18, 2009·Current Opinion in Infectious Diseases·Esteban MartínezJosé M Gatell
Jan 10, 2012·Current Opinion in HIV and AIDS·Shahin Lockman, Paul Sax
May 29, 2012·Current HIV/AIDS Reports·Markella V Zanni, Steven K Grinspoon
Feb 19, 2011·AIDS·Julia ThorpeUNKNOWN Canadian Co-infection Cohort Study (CTN222)
Feb 14, 2016·The Lancet. Diabetes & Endocrinology·Eric NouSteven K Grinspoon
Feb 23, 2010·Enfermedades infecciosas y microbiología clínica·Mar Masiá, Félix Gutiérrez
May 27, 2011·Journal of the International AIDS Society·Juan AmbrosioniBernard Hirschel
Dec 4, 2012·Arteriosclerosis, Thrombosis, and Vascular Biology·Byambaa EnkhmaaLars Berglund
Jun 30, 2016·Journal of the American Heart Association·Hossein BahramiWendy S Post
Oct 30, 2016·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Magdalena E SobieszczykNigel J Garrett
Aug 25, 2012·MMW Fortschritte der Medizin·Birgit MückHans Jäger
Aug 25, 2012·MMW Fortschritte der Medizin·Ulrich Seybold
Feb 23, 2011·Arquivos brasileiros de endocrinologia e metabologia·Clarisse Mourão Melo PonteRenan Magalhães Montenegro Júnior

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.